Clinical trial
A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in…
NCT00036569 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00036569 |
|---|---|
| Title | A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas |
| Official title | A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) in Children With Diffuse Pontine Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Intrinsic Pontine Glioma |
| Intervention type | Biological, Procedure |
| Interventions | adjuvant therapy, pegylated interferon alfa |
| Enrollment | 32 |
| Start date | May 1, 2002 |
| Primary completion | Dec 1, 2010 |
| Completion | Jan 1, 2012 |
| First posted | May 13, 2002 |
| Last update posted | Feb 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: